Atypical subtrochanteric femoral shaft fractures: role for mechanics and bone quality

Arthritis Research and Therapy

Volumn 14, Issue 4, 2012, Pages

  van der Meulen, Marjolein C H ^a   Boskey, Adele L ^b  

^a Cornell University   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; COLLAGEN; ETIDRONIC ACID; HYDROXYAPATITE; IBANDRONIC ACID; MINDRONIC ACID; NERIDRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

APOPTOSIS; ATYPICAL FEMORAL FRACTURE; BIOMECHANICS; BONE DENSITY; BONE MASS; BONE MINERAL; BONE MINERALIZATION; BONE RADIOGRAPHY; BONE REMODELING; BONE STRENGTH; BONE STRESS; BONE TURNOVER; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CORTICAL BONE; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR; FEMUR FRACTURE; FEMUR SHAFT FRACTURE; FEMUR SUBTROCHANTERIC FRACTURE; FIBER; FRACTURE; GEOMETRY; HIP FRACTURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK FACTOR; TISSUE CHARACTERIZATION; ANIMAL; FEMORAL FRACTURES; PHYSIOLOGY; RADIOGRAPHY;

ANIMALS; BIOMECHANICAL PHENOMENA; BONE DENSITY; BONE REMODELING; DIPHOSPHONATES; FEMORAL FRACTURES; HUMANS;

EID: 84865993900     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4013     Document Type: Review

References (67)

1. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90:1294-1301.
2. Siris ES, Pasquale MK, Wang Y, Watts NB. Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001-2008. J Bone Miner Res 2011, 26:3-11. 10.1002/jbmr.189, 20662073.
3. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M, . American Society for Bone and Mineral Research Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010, 25:2267-2294. 10.1002/jbmr.253, 20842676, American Society for Bone and Mineral Research.
4. Wang Q, Teo JW, Ghasem-Zadeh A, Seeman E. Women and men with hip fractures have a longer femoral neck moment arm and greater impact load in a sideways fall. Osteoporos Int 2009, 20:1151-1156. 10.1007/s00198-008-0768-y, 18931818.
5. Reilly DT, Burstein AH. The elastic and ultimate properties of compact bone tissue. J Biomech 1975, 8:393-405. 10.1016/0021-9290(75)90075-5, 1206042.
6. Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC, . Fracture Intervention Trial Steering Committee; HORIZON Pivotal Fracture Trial Steering Committee Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010, 362:1761-1771. 10.1056/NEJMoa1001086, 20335571, Fracture Intervention Trial Steering Committee; HORIZON Pivotal Fracture Trial Steering Committee.
7. Rizzoli R, Akesson K, Bouxsein M, Kanis JA, Napoli N, Papapoulos S, Reginster JY, Cooper C. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 2011, 22:373-390. 10.1007/s00198-010-1453-5, 3020314, 21085935.
8. Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 2010, 95:5258-5265. 10.1210/jc.2010-1571, 2999980, 20843943.
9. Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, Whelan DB, Weiler PJ, Laupacis A. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011, 305:783-789. 10.1001/jama.2011.190, 21343577.
10. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and diff erences and their potential infl uence on clinical efficacy. Osteoporos Int 2008, 19:733-759. 10.1007/s00198-007-0540-8, 18214569.
11. Russell RG. Bisphosphonates: the first 40 years. Bone 2011, 49:2-19. 10.1016/j.bone.2011.04.022, 21555003.
12. Ebetino FH, Hogan AM, Sun S, Tsoumpra MK, Duan X, Triffitt JT, Kwaasi AA, Dunford JE, Barnett BL, Oppermann U, Lundy MW, Boyde A, Kashemirov BA, McKenna CE, Russell RG. The relationship between the chemistry and biological activity of the bisphosphonates. Bone 2011, 49:20-33. 10.1016/j.bone.2011.03.774, 21497677.
13. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH. Novel insights into actions of bisphosphonates on bone: diff erences in interactions with hydroxyapatite. Bone 2006, 38:617-627. 10.1016/j.bone.2005.05.003, 16046206.
14. Rogers MJ, Crockett JC, Coxon FP, Monkkonen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 2011, 49:34-41. 10.1016/j.bone.2010.11.008, 21111853.
15. Bellido T, Plotkin LI. Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone 2011, 49:50-55. 10.1016/j.bone.2010.08.008, 2994972, 20727997.
16. Eastell R, Walsh JS, Watts NB, Siris E. Bisphosphonates for postmenopausal osteoporosis. Bone 2011, 49:82-88. 10.1016/j.bone.2011.02.011, 21349354.
17. Le Goff B, Berthelot JM, Maugars Y, Romas E. Alternative use of bisphosphonate therapy for rheumatic disease. Curr Pharm Des 2010, 16:3045-3052. 10.2174/138161210793563626, 20722620.
18. Bilezikian JP. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med 2009, 122(2 Suppl):S14-21.
19. Brandi ML. Sustained vertebral antifracture efficacy of oral antiosteoporotic therapies in postmenopausal osteoporosis. Curr Med Res Opin 2010, 26:2553-2563. 10.1185/03007995.2010.519658, 20858031.
20. Zhong ZM, Chen JT. Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials. Clin Drug Investig 2009, 29:349-357. 10.2165/00044011-200929050-00007, 19366276.
21. Meunier PJ, Arlot M, Chavassieux P, Yates AJ. The eff ects of alendronate on bone turnover and bone quality. Int J Clin Pract Suppl 1999, 101:14-17.
22. Eastell R, Hannon RA. Biomarkers of bone health and osteoporosis risk. Proc Nutr Soc 2008, 67:157-162. 10.1017/S002966510800699X, 18412989.
23. Bergmann P, Body JJ, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, Kaufman JM, Reginster JY, Gangji V. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract 2009, 63:19-26. 2705815, 19125989.
24. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002, 112:281-289. 10.1016/S0002-9343(01)01124-X, 11893367.
25. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282:637-645. 10.1001/jama.282.7.637, 10517716.
26. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M. Eff ect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995, 333:1437-1443. 10.1056/NEJM199511303332201, 7477143.
27. Riggs BL, Melton LJ, O'Fallon WM. Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone 1996, 18(3 Suppl):197S-201S.
28. Fraser LA, Vogt KN, Adachi JD, Thabane L. Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis. Ther Clin Risk Manag 2011, 7:157-166. 3116803, 21691586.
29. Rodan G, Reszka A, Golub E, Rizzoli R. Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 2004, 20:1291-1300. 10.1185/030079904125004475, 15324532.
30. Pazianas M, Abrahamsen B. Safety of bisphosphonates. Bone 2011, 49:103-110. 10.1016/j.bone.2011.01.003, 21236370.
31. Beck TJ, Ruff CB, Shaffer RA, Betsinger K, Trone DW, Brodine SK. Stress fracture in military recruits: gender differences in muscle and bone susceptibility factors. Bone 2000, 27:437-444. 10.1016/S8756-3282(00)00342-2, 10962357.
32. Pohl MB, Mullineaux DR, Milner CE, Hamill J, Davis IS. Biomechanical predictors of retrospective tibial stress fractures in runners. J Biomech 2008, 41:1160-1165. 10.1016/j.jbiomech.2008.02.001, 18377913.
33. Tommasini SM, Nasser P, Schaffler MB, Jepsen KJ. Relationship between bone morphology and bone quality in male tibias: implications for stress fracture risk. J Bone Miner Res 2005, 20:1372-1380. 10.1359/JBMR.050326, 16007335.
34. Allen MR, Burr DB. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know. Bone 2011, 49:56-65. 10.1016/j.bone.2010.10.159, 20955825.
35. Allen MR, Follet H, Khurana M, Sato M, Burr DB. Antiremodeling agents influence osteoblast activity differently in modeling and remodeling sites of canine rib. Calcif Tissue Int 2006, 79:255-261. 10.1007/s00223-006-0031-5, 17033724.
36. Allen MR, Reinwald S, Burr DB. Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment. Calcif Tissue Int 2008, 82:354-360. 10.1007/s00223-008-9131-8, 2698704, 18463913.
37. Tang SY, Allen MR, Phipps R, Burr DB, Vashishth D. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int 2009, 20:887-894. 10.1007/s00198-008-0754-4, 2733909, 18850239.
38. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000, 15:613-620.
39. Tjhia CK, Odvina CV, Rao DS, Stover SM, Wang X, Fyhrie DP. Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects. Bone 2011, 49:1279-1289. 10.1016/j.bone.2011.09.042, 21958843.
40. Boskey AL, Donnelly E, Kinnett JG. Bone quality: from bench to bedside: opening editorial comment. Clin Orthop Relat Res 2011, 469:2087-2089. 10.1007/s11999-011-1785-2, 3126974, 21344274.
41. Ito M, Nakata T, Nishida A, Uetani M. Age-related changes in bone density, geometry and biomechanical properties of the proximal femur: CT-based 3D hip structure analysis in normal postmenopausal women. Bone 2011, 48:627-630. 10.1016/j.bone.2010.11.007, 21087686.
42. Melton LJ, Riggs BL, Keaveny TM, Achenbach SJ, Hoff mann PF, Camp JJ, Rouleau PA, Bouxsein ML, Amin S, Atkinson EJ, Robb RA, Khosla S. Structural determinants of vertebral fracture risk. J Bone Miner Res 2007, 22:1885-1892. 10.1359/jbmr.070728, 17680721.
43. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008, 358:1304-1306. 10.1056/NEJMc0707493, 18354114.
44. Takakuwa M, Iwamoto J, Konishi M, Zhou Q, Itabashi K. Risedronate improves proximal femur bone density and geometry in patients with osteoporosis or osteopenia and clinical risk factors of fractures: a practicebased observational study. J Bone Miner Metab 2011, 29:88-95. 10.1007/s00774-010-0196-x, 20533068.
45. Hochberg MC, Rizzoli R. Long-term experience with alendronate in the treatment of osteoporosis. Expert Opin Pharmacother 2006, 7:1201-1210. 10.1517/14656566.7.9.1201, 16732706.
46. Unnanuntana A, Ashfaq K, Ton QV, Kleimeyer JP, Lane JM. The effect of longterm alendronate treatment on cortical thickness of the proximal femur. Clin Orthop Relat Res 2012, 470:291-298. 10.1007/s11999-011-1985-9, 21773861.
47. Koh JS, Ng AC, Png MA, Howe TS. Letter to the editor: the effect of longterm alendronate treatment on cortical thickness of the proximal femur. Clin Orthop Relat Res 2011, 469:3509-3510. author reply 3511-3512, 10.1007/s11999-011-2129-y, 21997786.
48. Chavassieux P, Seeman E, Delmas PD. Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. Endocr Rev 2007, 28:151-164.
49. Donnelly E, Meredith DS, Nguyen JT, Gladnick BP, Rebolledo BJ, Shaffer AD, Lorich DG, Lane JM, Boskey AL. Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. J Bone Miner Res 2012, 27:672-678. 10.1002/jbmr.560, 22072397.
50. Vashishth D. The role of the collagen matrix in skeletal fragility. Curr Osteoporos Rep 2007, 5:62-66. 10.1007/s11914-007-0004-2, 17521507.
51. Banse X, Sims TJ, Bailey AJ. Mechanical properties of adult vertebral cancellous bone: correlation with collagen intermolecular cross-links. J Bone Miner Res 2002, 17:1621-1628. 10.1359/jbmr.2002.17.9.1621, 12211432.
52. Paschalis EP, Tatakis DN, Robins S, Fratzl P, Manjubala I, Zoehrer R, Gamsjaeger S, Buchinger B, Roschger A, Phipps R, Boskey AL, Dall'Ara E, Varga P, Zysset P, Klaushofer K, Roschger P. Lathyrism-induced alterations in collagen crosslinks influence the mechanical properties of bone material without affecting the mineral. Bone 2011, 49:1232-1241. 10.1016/j.bone.2011.08.027, 3229977, 21920485.
53. Wang X, Shen X, Li X, Agrawal CM. Age-related changes in the collagen network and toughness of bone. Bone 2002, 31:1-7. 10.1016/S8756-3282(01)00697-4, 12110404.
54. Durchschlag E, Paschalis EP, Zoehrer R, Roschger P, Fratzl P, Recker R, Phipps R, Klaushofer K. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. J Bone Miner Res 2006, 21:1581-1590. 10.1359/jbmr.060701, 16995813.
55. O'Brien FJ, Brennan O, Kennedy OD, Lee TC. Microcracks in cortical bone: how do they affect bone biology?. Curr Osteoporos Rep 2005, 3:39-45. 10.1007/s11914-005-0002-1, 16036100.
56. Chapurlat RD, Arlot M, Burt-Pichat B, Chavassieux P, Roux JP, Portero-Muzy N, Delmas PD. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res 2007, 22:1502-1509. 10.1359/jbmr.070609, 17824840.
57. Miller LM, Little W, Schirmer A, Sheik F, Busa B, Judex S. Accretion of bone quantity and quality in the developing mouse skeleton. J Bone Miner Res 2007, 22:1037-1045. 10.1359/jbmr.070402, 17402847.
58. Gourion-Arsiquaud S, Faibish D, Myers E, Spevak L, Compston J, Hodsman A, Shane E, Recker RR, Boskey ER, Boskey AL. Use of FTIR spectroscopic imaging to identify parameters associated with fragility fracture. J Bone Miner Res 2009, 24:1565-1571. 10.1359/jbmr.090414, 2730929, 19419303.
59. Gamsjaeger S, Buchinger B, Zwettler E, Recker R, Black D, Gasser JA, Eriksen EF, Klaushofer K, Paschalis EP. Bone material properties in actively boneforming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid. J Bone Miner Res 2011, 26:12-18. 10.1002/jbmr.180, 20645415.
60. Boskey AL, Spevak L, Weinstein RS. Spectroscopic markers of bone quality in alendronate-treated postmenopausal women. Osteoporos Int 2009, 20:793-800. 10.1007/s00198-008-0725-9, 2664862, 18769963.
61. Gourion-Arsiquaud S, Allen MR, Burr DB, Vashishth D, Tang SY, Boskey AL. Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity. Bone 2010, 46:666-672. 10.1016/j.bone.2009.11.011, 2823979, 19925895.
62. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier P J. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000, 27:687-694. 10.1016/S8756-3282(00)00376-8, 11062357.
63. Nuzzo S, Lafage-Proust MH, Martin-Badosa E, Boivin G, Thomas T, Alexandre C, Peyrin F. Synchrotron radiation microtomography allows the analysis of three-dimensional microarchitecture and degree of mineralization of human iliac crest biopsy specimens: effects of etidronate treatment. J Bone Miner Res 2002, 17:1372-1382. 10.1359/jbmr.2002.17.8.1372, 12162491.
64. Ott SM. What is the optimal duration of bisphosphonate therapy?. Cleveland Clin J Med 2011, 78:619-630.
65. Odvina CV, Levy S, Rao S, Zerwekh JE, Rao DS. Unusual mid -shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf) 2010, 72:161-168.
66. Somford MP, Draijer FW, Thomassen BJ, Chavassieux PM, Boivin G, Papapoulos SE. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res 2009, 24:1736-1740. 10.1359/jbmr.090408, 19419297.
67. Aspenberg P, Schilcher J, Fahlgren A. Histology of an undisplaced femoral fatigue fracture in association with bisphosphonate treatment. Frozen bone with remodelling at the crack. Acta Orthop 2010, 81:460-462. 10.3109/17453674.2010.492766, 2917569, 20515438.